Skip to main content

Tweets

Infections in pre-RA: a cause or a consequence? Dr. Aurelie Najm ( @AurelieRheumo) discusses oral presentation abstract #0535 from #ACR22. https://t.co/ajI2zo4KRA https://t.co/cHkzNshVcn
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
Proposed Cancer Screening for Inflammatory Myositis Patients 11/12's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer. https://t.co/uMhJu6eQt1 https://t.co/JeeeGadP4d
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
#ACR22 Appraisal, Praise & Critique Dr. Cush talks ACR22, the highs and the lows. https://t.co/NoRqvFaBKl https://t.co/0b5IlAojVq
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
Exciting Data for SLE: Plenaries from #ACR22 Dr. Michael Putman ( @EBRheum ) shares SLE updates shared at #ACR22. https://t.co/e6tCwLdHMS https://t.co/u7yoE4T9Zs
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
Dual target blockade may be better than one in SLE Dr. Yusof ( @Yuz6Yusof) discusses abstracts #L07 and #1001 presented at #ACR22. https://t.co/0SzQAorzZy https://t.co/fZ6CpFNSWI
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
Lupus Topic Panel Join RheumNow to recap the best and most interesting data presented at #ACR22 in the area of SLE. Panelists: @KDAO2011 @bella_mehta @Yuz6Yusof @ericdeinmd @EBRheum @RHEUMarampa @Janetbirdope https://t.co/7oUZcQK27U https://t.co/1JClivUJpk
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
2022 ACR/EULAR Classification Criteria for GCA Dr. Michael Putman discusses interesting take-home messages from the Vasculitis Investigators Meeting at ACR22 Convergence regarding the 2022 ACR/EULAR Classification Criteria for GCA. https://t.co/FL9FGhWcxB https://t.co/JKi7Nn4O2O
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
Avoid Abatacept in RA patients with a history of cancer? Dr. Richard Conway ( @RichardPAConway ) discusses abstracts #0267 and #0255 presented at #ACR22. https://t.co/1lC33XlBt7 https://t.co/ttUQaTVF43
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
Anifrolumab shows long-term promise in patients with lupus Researchers report positive results from the first placebo-controlled long-term trial of anifrolumab—a human monoclonal antibody that targets the type I IFN receptor—in patients with lupus. https://t.co/IlgEUKkMOv https://t.co/kpSt61d5Qx
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
Effect of voclosporin in class V lupus nephritis Dr. Yusof ( @Yuz6Yusof) discusses abstract 0355 presented at #ACR22. Abstract 0355: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study https://t.co/sH04dhBskS https://t.co/mUOrJKdYBF
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
#ACR22 - Day 1 https://t.co/GlEhTnKXm7 https://t.co/JFyMSpjFq3
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
JAK vs TNF inhibitor Infections in RA Dr. David Liew ( @drdavidliew) discusses abstract 0302 at #ACR22 Convergence. Abstract 0302: Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis https://t.co/ipD5ON7BJ7 https://t.co/rRD5wqHhFk
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
×